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Neonatal abstinence syndrome (NAS) is a condition affecting newborns  
exposed to an opioid in utero. Symptoms of NAS include excessive crying, 
poor feeding, and disordered autonomic control. Up to 2/3 of infants will 
require pharmacologic therapies to reach symptom control. Opioids 
including morphine and methadone are the current first-line treatments. 
Buprenorphine is being investigated as a treatment of NAS. The purpose of 
this analysis was to evaluate the pharmacokinetics (PK) and 
pharmacodynamics (PD) of BUP in infants with NAS.  
The Blinded Buprenorphine OR Neonatal morphine solution (BBORN) trial 
(NCT01452789) was a  double-blind, double-dummy, randomized, controlled 
trial that assessed the efficacy of buprenorphine and morphine in NAS. 
Blood was analyzed from patients who received buprenorphine.  All infants 
were monitored using the MOTHER NAS Scale, a modified Finnegan scoring 
instrument. 
 
Term infants were treated for NAS if they had 3 scores >24 or a single score 
>12. The neonates allocated to the buprenorphine group were treated with 
sublingual buprenorphine 5.3 µg/kg every eight hours. Doses were up-
titrated by 25% for inadequate symptom control up to a maximal dose of 20 
µg/kg.  
 
When the infant was stabilized, the dose was tapered at a rate of 10% daily 
until within 10% of the starting dose. Blood for PK analysis was drawn in all 
study patients using a sparse sampling regimen. Buprenorphine and 
norbuprenorphine concentrations were analyzed using liquid 
chromatography/mass spectrometry. The limit of quantification was 0.1 
ng/mL for both buprenorphine and norbuprenorphine.  
 
The data were used to validate and adapt an existing model of 
buprenorphine PK in neonates (Ng CM,. Pharmacotherapy. 2015 
Jul;35(7):670-80. PMID 26172282). This reference model utilized a 2-
compartment model with PK parameters scaled allometrically by weight and 
maturation functions on clearance and peripheral volume of distribution. 
The model was then extended to norbuprenorphine. Norbuprenorphine 
formation was modeled as a fraction of previously established clearance of 
buprenorphine given the potential for buprenorphine to be metabolized by 
multiple pathways. The metabolite PK parameters were also scaled by 
weight allometrically. The buprenorphine/norbuprenorphine data were 
analyzed against the NAS scores to identify potential PD relationships. The 
knowledge of the relationship was used to link the PK to a PD model of NAS. 
a) 1000 simulations of average NAS score. The solid line 
and blue shaded area represent the median and 95% CI 
of the simulation, and the dashed lines represent the 
median and 95% CI of the observed data.  
 
b) Histogram of 1000 simulated times to stabilization with 
the dotted lines as the median and 95% CI of the 
simulation. Black line is median of the observed data.  
 
These graphs further demonstrate that the PD model was 
effective in the description of the course of NAS and  
the time to stabilization. 
• The findings confirm an existing PK model of buprenorphine in neonates and extend the model to describe the PK of norbuprenorphine and the PD of buprenorphine in NAS.  
• This is the first PD model of a drug effect in NAS. It appeared to well describe relevant features of the NAS disease course.  
• Exposure to buprenorphine was linked to stabilization of NAS. Clearance as the inverse of exposure appeared to be the primary driver of clinical efficacy. 
• This PK-PD model can be used to simulate dose regimens which may facilitate quicker stabilization or less frequent dosing.  
Patient Demographics 
PK and PD Model Parameters 
172 buprenorphine/norbuprenorphine serum 
concentrations and 4373 NAS scores were 
collected from 28 full term infants. The 
reference model from a Phase 1 trial was shown 
to reasonably predict the new data with mean 
squared error of 0.062 and root mean squared 
error of 0.251.  
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The goodness-of-fit (GOF) plots demonstrate that the model was generally able to describe the data well.  
Exposure to buprenorphine drives clinical efficacy in 
NAS. The graphs show that time to stabilization of NAS 
was linked to the initial severity  of NAS and the total 
exposure to buprenorphine. In Figure 5, neonates with 
higher clearances were exposed to less study agent 
and had higher times to stabilization. Figure 6 shows 
that more severe NAS generally required a higher AUC 
of buprenorphine to stabilize. Figure 7 demonstrates 
that higher average concentrations of buprenorphine 
were correlated  with faster time to stabilization. 
Figure 1. PK and PD Model Schematic 
Figure 2. Buprenorphine GOF Figure 3. Norbuprenorphine GOF Figure 4. NAS Score GOF 
Figure 7. Relationship Between Average Concentration 
of Buprenorphine and Time to Stabilization 
Figure 6. NAS Severity Influenced Required Buprenorphine 
Exposure 
Figure 5. Relationship Between Clearance 
of Buprenorphine and Time to Stabilization 
Figure 8. NAS Predictive Checks 
